Monday, October 12, 2020 Daily Archives

Ocugen signs deal with Indian CMO to avoid US capacity constraints

by

Ocugen has signed a manufacturing deal with Kemwell Biopharma for a potential treatment of retinal diseases. The two companies entered the agreement for the clinical production of Ocu200, a novel biologic candidate that could enter clinical trials in 2022. Ocu200 will first be tested to treat diabetic macular edema (DME), but Ocugen also stated that, depending on clinical success, it could seek to expand treatment targets to diabetes retinopathy and wet-age related macular degeneration. The potential therapy is a novel…

October 12, 2020

Lusk for life: Abzena $60m plant to support Ph III and commercial biologics

by

Abzena has begun operations at its 50,000 square-foot ‘Lusk’ facility boasting single-use bioreactors up to 2,000 L to support late-stage and commercial biologics. Contract development and manufacturing organization (CDMO) Abzena has further expanded its biologics offering, opening a $60 million facility in San Diego, California. The site houses a process development laboratory, two cGMP manufacturing cleanrooms for 500 L and 2,000 L scale bioreactors, a GMP warehouse, and analytical development and quality control (QC) laboratories. “We are already operational and…

October 12, 2020

Lilly hires Fujifilm Diosynth Biotechnologies to make COVID-19 mAbs

by

Eli Lilly has added Fujifilm Diosynth Biotechnologies to the list of firms manufacturing its candidate COVID-19 antibody therapies. The contract – which is part of Lilly’s agreement with the Bill & Melinda Gates Foundation – will see Fujifilm Diosynth Biotechnologies make commercial supplies of the product at its facility in Hillerod, Denmark. Production is expected to start in April next year. The facility – which was acquired from Biogen last year – houses six 20,000 L bioreactors for the production…

October 12, 2020